2022
DOI: 10.1039/d1dt04095b
|View full text |Cite
|
Sign up to set email alerts
|

Complexes of Zn(ii) with a mixed tryptanthrin derivative and curcumin chelating ligands as new promising anticancer agents

Abstract: In this study, two novel curcumin (H-Cur)–tryptanthrin metal compounds—[Zn(TA)Cl2], i.e., Zn(TA), and [Zn(TA)(Cur)]Cl, i.e., Zn(TAC)—were synthesized and investigated using 5-(bis-pyridin-2-ylmethyl-amino)-pentanoic acid (6,12-dioxo-6,12-dihydro-indolo[2,1-b]quinazolin-8-yl)-amide (TA) and H-Cur as the targeting and high-activity...

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
18
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 21 publications
(18 citation statements)
references
References 105 publications
0
18
0
Order By: Relevance
“…In an A549CDDP model, the effect of RhS and RhQ on tumor growth was investigated in vivo. 33,76–79 As shown in Fig. 8, intraperitoneal injections of RhS (5.0 mg kg −1 ) and RhQ (5.0 mg kg −1 ) every two days resulted in significant inhibition of A549CDDP tumor growth in vivo , with up to 46.4% and 55.3% inhibition of tumor growth after 15.0 days, respectively (Fig.…”
Section: Resultsmentioning
confidence: 85%
See 2 more Smart Citations
“…In an A549CDDP model, the effect of RhS and RhQ on tumor growth was investigated in vivo. 33,76–79 As shown in Fig. 8, intraperitoneal injections of RhS (5.0 mg kg −1 ) and RhQ (5.0 mg kg −1 ) every two days resulted in significant inhibition of A549CDDP tumor growth in vivo , with up to 46.4% and 55.3% inhibition of tumor growth after 15.0 days, respectively (Fig.…”
Section: Resultsmentioning
confidence: 85%
“…8 and Tables S14–S16†). It was interesting to note that RhQ exhibited significantly more potency than RhS and CDDP (33.1%), 33,76,77 with less toxicity and weight change (Fig. 8 and Tables S14–S16†).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…3–6 The zinc( ii ) ion is a bioessential transition metal ion for the growth and death of organisms, the development of all fundamental biological processes, and the occurrence of some diseases. 7–10 Additionally, many zinc( ii ) metal complexes containing, for example, Zn( ii )-3-bromo-5-chloro-salicylaldehyde compounds, 1 zinc( ii )-bis(dipyrrinato)/porphyrin/phthalocyanine compounds, 11 zinc( ii )-benzothiazolyl/dithiocarbazate compounds, 12 zinc( ii )-cryptolepine compounds, 13 zinc( ii )-boron-dipyrromethene compounds, 9,14 zinc( ii )-terpyridine compounds, 15 zinc( ii )-bis(pyrazolyl)methane compounds, 16 zinc( ii )-thiosemicarbazone–alkylthiocarbamate compounds, 17 zinc( ii )-Schiff-base compounds, 18 and zinc( ii )-mixed tryptanthrin derivatives 19 have been shown to exhibit intriguing anticancer activity. However, little data have been obtained regarding the cytotoxicity of zinc( ii ) metal coordination compounds against human tumor cells in the field of medicine.…”
Section: Introductionmentioning
confidence: 99%
“…The Pt-based drug cisplatin and its related complexes comprise the first line of treatment for various types of neoplasms in the fight against cancer. 1–3 However, the clinical application of cisplatin and its analogues has been limited due to their side effects, such as neurotoxicity, drug resistance, emetogenicity, and nephrotoxicity. 4 To overcome these drawbacks, a large number of non-platinum anticancer drugs with less toxicity, greater effectiveness, and higher target specificity have been discovered.…”
Section: Introductionmentioning
confidence: 99%